Massachusetts Lawmakers Prioritize Health Policy
Katherine O'Malley
August 12, 2026
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
The Evolving Roles of the Medical Journal, by Scott H. Podolsky, Jeremy A. Greene, and David S. Jones (The New England Journal of Medicine) Making the
When Austin first sent me this link, I was skeptical: Maryland teachers were instructed to engage children by crouching and speaking to them at eye
Apropos of nothing, I’ve been feeling very tired lately. I know I haven’t been getting enough sleep. That’s partly because I’ve been working a bit
It’s cliché to say the devil (or God) is in the details. Nevertheless, it’s true for so many things and is particularly apt for Medicare
UPDATE: The language in question is still [bracketed] text, meaning the House Committee has not agreed yet on the language. Markup is today (Thursday) starting
A very important policy question today is, what exerts greater cost control, supply- or demand-side cost sharing? The former puts the cost risk on providers
This post is coauthored by Austin Frakt and Aaron Carroll. Christopher Flavelle has put together a fascinating Bloomberg Government Study on the allure and growth
From The Economist: UPDATE: based on a 2011 Lancet article, abstract here @koutterson
I’m still getting hate mail because of that piece I wrote on doctors “struggling to make ends meet“. Guess I can’t help myself. Here we
I somehow missed this when it came out, but it’s worth a listen! Sound Medicine is a radio show produced by the Indiana University School of Medicine and WFYI
We have strong evidence that the patent system is functioning poorly, with low quality patents, indistinct property boundaries and lots of wasteful litigation. (See Bessen
New paper out in Health Affairs, “In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In